Iluvien 12-month results

Article

The Iluvien fluocinolone acetonide intravitreal insert (Alimera Sciences, Inc) is safe and effective in the management of diabetic macular oedema (DME) at twelve months, according to study results released by Alimera.

The Iluvien fluocinolone acetonide intravitreal insert (Alimera Sciences, Inc) is safe and effective in the management of diabetic macular oedema (DME) at twelve months, according to study results released by Alimera.

The ongoing 36-month Phase II open-label pharmacokinetic study is designed to assess the extent of systemic exposure to fluocinolone acetonide following Iluvien implantation and to assess the safety and efficacy of the insert. Of the 37 patients enrolled in the study, 20 received a dose of 0.23 µg daily, and the remaining 17 received 0.45 µg per day.

Of the patients on the high dose, 27.3% experienced a 15 letter or greater increase in best corrected visual acuity (BCVA); among low dose patients, this was 23.1%. None of the low-dose patients experienced intraocular pressure (IOP)-related adverse events; however, 23.5% of the high dose patients suffered IOP increases of ≥30 mmHg at some point throughout the study period. This was no increase over the IOP raises seen at the previous three and six month follow-up visits.

Alimera claims that these results are as expected for Iluvien at this time point. The next data will be available from the study at the 18-month time point.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.